PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2025 and raised its full year 2025 guidance. The company reported revenue of $2.5 billion for the second quarter of 2025, an increase of 4% compared with the second quarter of 2024. On an organic operational1 basis, revenue for the second quarter of 2025 increased 8% compared with the second quarter of 2024. Net income for the second quarter of 2025 was $718 million, or $1.61
Related Questions
How might the market react to the combination of modest topâline growth and a higher net income in terms of shortâterm price movement and trading volume?
Are there any macro or regulatory factors (e.g., veterinary drug approvals, petâinsurance penetration) that could materially alter the raised guidance?
What technical or fundamental chart patterns are emerging for ZTS following this earnings release, and could they indicate a breakout or a pullâback?
How does Zoetis' 2025 revenue growth trajectory compare to its main competitors in the animalâhealth space, such as Merck Animal Health and Bayerâs Animal Health division?
What is the projected operating margin for the full year, and does the revised guidance suggest margin expansion or costâcontainment initiatives?
Will the higher net income of $718âŻmillion (â$1.61âŻEPS) translate into a stronger dividend outlook or shareârepurchase program?
How will the 4% yearâoverâyear revenue growth and 8% organic growth affect market expectations for Zoetis' growth momentum?
What is the implied forwardâlooking earnings per share (EPS) based on the raised fullâyear 2025 guidance, and how does it compare to consensus estimates?
How might the upward revision of fullâyear 2025 outlook influence the stockâs valuation multiples (e.g., EV/Revenue, P/E) relative to peers?
What are the key drivers behind the organic revenue increaseânew product launches, market share gains, or pricing initiatives?